	Case 2:14-cv-00653-JWS Document 1 Filed 03/31/14 Page 1 of 13						
1	C. Mark Kittredge (#013907)						
2	MKittredge@perkinscoie.com K. Reed Willis (#028060)						
3	RWillis@perkinscoie.com PERKINS COIE LLP						
4	2901 North Central Avenue, Suite 2000 Phoenix, Arizona 85012-2788						
5	Telephone: 602.351.8000 Facsimile: 602.648.7000						
6	DocketPHX@perkinscoie.com						
7	Attorneys for Plaintiff The Arizona Board of Regents						
8	UNITED STATES DISTRICT COURT						
9	DISTRICT OF ARIZONA						
10							
11	The Arizona Board of Regents for and on behalf of Arizona State University,	No.					
12	Plaintiff,	COMPLAINT FOR INFRINGEMENT OF U.S. PATENT					
13	V.	NO. 5,635,483					
14	Seattle Genetics, Inc.,	AND					
15	Defendant.	DEMAND FOR JURY TRIAL					
16							
17	Plaintiff The Arizona Board of Regents for and on behalf of Arizona State						
18	University (collectively "ASU"), on personal information as to its own acts, and on						
19	information and belief as to all others, for its complaint against Defendant Seattle						
20	Genetics, Inc. ("Seattle Genetics"), alleges as follows.						
21	Introduction						
22	1. Dr. Robert Pettit, an organic chemistry professor at Arizona State University,						
23	is one of the most prominent natural products chemists in the world. His life's work has						
24	focused on developing novel anticancer drugs from natural sources.						
25	2. In 1977, Dr. Pettit isolated several potential anticancer compounds from a						
26	sea hare species found in the Indian Ocean. In 1982, he named one of the most promising						
27	compounds Dolastatin 10. Initial scientific studies carried out in Dr. Pettit's laboratory						
28	indicated that Dolastatin 10 was a potent anticancer agent and thus, over the next couple						

Case 2:14-cv-00653-JWS Document 1 Filed 03/31/14 Page 2 of 13

of decades, Dolastatin 10 underwent extensive preclinical and clinical testing for the
 treatment of various types of cancer.

3 3. In an effort to continue to develop promising anticancer drugs, Dr. Pettit's 4 laboratory synthesized a number of chemical analogues of Dolastatin 10. One class of 5 these new Dolastatin 10 analogues named the Auristatins was the subject of U.S. Patent 6 No. 5,635,483 (the "483 patent"), issued to Dr. Pettit and ASU (as the assignee) on June 7 3, 1997. The '483 patent entitled "Tumor Inhibiting Tetrapeptide Bearing Modified 8 Phenethyl Amides" claims a range of chemical compounds and methods for treating 9 cancer with such chemical compounds. The chemical compounds disclosed and claimed 10 by the '483 patent include a number of species of a chemical compound known as 11 Auristatin E.

4. Seattle Genetics makes or has made, markets, offers to sell and sells a Food
and Drug Administration ("FDA") approved antibody drug conjugate ("ADC") under the
name ADCETRIS[®]. The cytotoxic agent, or drug, in the ADCETRIS[®] ADC is a chemical
compound known as monomethyl Auristatin E ("MMAE"). MMAE and ADCETRIS[®],
which incorporates and delivers MMAE, infringe the '483 patent, as outlined more fully
below.

18

Parties, Jurisdiction And Venue

19 5. Plaintiff The Arizona Board of Regents is a body corporate established
20 under the Arizona Constitution and pursuant to A.R.S. § 15-1625 and has authority to act
21 for and on behalf of Arizona State University. ASU is the assignee of the '483 patent, and
22 holds all rights to the '483 patent.

6. Plaintiff is informed and believes, and therefore alleges, that Defendant
Seattle Genetics is a Delaware Corporation having its principal place of business in
Bothell, Washington.

7. This is an action for patent infringement arising under the patent laws of the
United States, 35 U.S.C. § 1 *et seq*. This Court has original subject matter jurisdiction
pursuant to 28 U.S.C. §§ 1331 and 1338.

-2-

Case 2:14-cv-00653-JWS Document 1 Filed 03/31/14 Page 3 of 13

8. Seattle Genetics has ongoing and systematic contacts with the State of
 Arizona and this judicial district. On information and belief, Seattle Genetics is registered
 to conduct business in Arizona. On information and belief, Seattle Genetics is also
 conducting business in this state and judicial district by, among other things, selling
 and/or offering to sell ADCETRIS[®] within this district. By so doing, Seattle Genetics has
 infringed ASU's patent rights in Arizona. As a result, this Court has personal jurisdiction
 over Seattle Genetics.

9. This Court has personal jurisdiction over Seattle Genetics as it entered into a
license agreement with ASU under the '483 patent, and negotiated and executed an
amendment in 2004, which specifically recognized that MMAE is not one of the licensed
compounds. Seattle Genetics' specific and ongoing contacts with Arizona relate to the
infringement of the '483 patent. As a result, this Court has personal jurisdiction over
Seattle Genetics.

14 10. Pursuant to 28 U.S.C. § 1391(b)(2), this Court is a proper venue for this
15 action.

16

Summary Of The Controversy

17 11. Dr. Pettit's life work has been to find life-saving anticancer drugs. One of
18 his most significant discoveries is Auristatin E, a powerful anticancer drug that could be
19 linked with a monoclonal antibody to form a targeted cancer treatment called an antibody
20 drug conjugate. ASU licensed this technology to Seattle Genetics to develop an ADC.

12. To develop its ADC, Seattle Genetics minimally modified the dimethyl
form of Auristatin E and claimed that the modification is not covered by the '483 patent.
Seattle Genetics' modification, however, does not allow it to avoid infringement of
the '483 patent.

25

A. Dr. Pettit Discovered Dolastatin And Synthesized Auristatin

In the late 1960's, Dr. Pettit and the National Cancer Institute began a
systematic study of marine plants and animals. In the fall of 1972, their research focused
on animals and plants in the Western Indian Ocean. Dr. Pettit's team identified the sea

-3-

Case 2:14-cv-00653-JWS Document 1 Filed 03/31/14 Page 4 of 13

1 hare *Dolabella auricularia* as possessing anticancer properties, and isolated several 2 Dolastatin compounds for further study.

3 14. Out of the identified compounds, Dolastatin 10 was one of the most 4 promising anticancer drugs, because it potently interfered with cell division, a common 5 strategy for treating cancer.

15. Over the next ten years, Dr. Pettit worked to synthesize usable Dolastatin analogues. One class of analogues he synthesized came to be known as Auristatins.

8

10

11

12

13

14


6

7

9

is:

The chemical structure of Auristatin E, which is most relevant for this case, 16.



15 Auristatin E is a cytotoxic agent and has been shown to potently kill cancer cells. 16 Auristatin E kills cancer cells, for example, by interfering with how such cancer cells 17 reproduce, specifically how they divide.

18 17. Each normal cell in the human body contains a set of chromosomes which 19 contain genetic information that is important in ensuring the cell functions properly. 20 During periods of growth, when a cell divides to create new "daughter" cells, the 21 chromosomes must be copied or "replicated" to ensure each daughter cell receives a 22 complete set of genetic information.

23

18. Cellular structures known as "microtubules" physically separate each set of 24 chromosomes to their respective daughter cell. Once normal cell division is complete, if 25 microtubules are functioning properly, each daughter cell will have a complete set of 26 chromosomes or genetic information.

- 27
- 28

2

3

5

6

7

1

19. In general, one of the hallmarks of cancer cells is that they divide uncontrollably, which leads to formation of tumors. Thus, a common strategy for treating cancer is to use chemical compounds that kill dividing cells.

4

20. Compounds claimed by the '483 patent, such as Auristatin E, kill cancer cells by, for example, disrupting microtubules. Auristatin E disrupts microtubules by binding to a protein making up microtubules called "tubulin." Much like a lock and key, Auristatin E (the key) binds to the tubulin protein at a very specific location (the lock).

8 21. Tubulin is a dynamic protein. In order to have properly-functioning
9 microtubules, the tubulin protein must be able to "polymerize" or "assemble" into long
10 linear chains.

11 22. When Auristatin E binds to tubulin, the tubulin protein cannot polymerize. 12 This causes microtubules to malfunction resulting in chromosomes that are not properly 13 separated into each daughter cell. Because each daughter cell does not have the proper 14 number of chromosomes, each cell undergoes a process known as "apoptosis" or 15 "programmed cell death" and the cells die.

Dr. Pettit applied for a patent covering his Auristatin analogues on
December 3, 1992, which the United State Patent and Trademark Office issued as U.S.
Patent No. 5,635,483, entitled "TUMOR INHIBITING TETRAPEPTIDE BEARING
MODIFIED PHENETHYL AMIDES," on June 3, 1997 (attached as Exhibit 1). The '483
patent claims several Auristatin analogues including Auristatin E.

- 21
- 22

B. ASU Licensed Four Specific Stereoisomers In The '483 Patent To Seattle Genetics

23 24. Seattle Genetics had started developing ADCs but needed a potent cancer
24 killing drug that it could link to an appropriate antibody. Recognizing the groundbreaking
25 nature of Dr. Pettit's research, Seattle Genetics approached Dr. Pettit and began
26 discussing the possibility of using his compounds for ADC development.

27 25. On August 14, 1998, Peter Senter, a scientist from Seattle Genetics, wrote
28 Dr. Pettit seeking assistance on the use of drugs developed by Dr. Pettit at ASU. Dr. Pettit

-5-

Case 2:14-cv-00653-JWS Document 1 Filed 03/31/14 Page 6 of 13

told Seattle Genetics to use Auristatin E with its then existing antibodies and linker technologies. Seattle Genetics sought to obtain from Dr. Pettit, and did in fact obtain, extensive information on the structure of the Auristatin E family, process for manufacturing it and critical information on its biological activity. Seattle Genetics received a copy of the '483 patent and reagents, including certain forms of Auristatin E and other compounds for testing and development.

7

8

14

15

16

17

18


19

20

26. Pursuant to a signed secrecy agreement Seattle Genetics received confidential information regarding Dr. Pettit's Auristatin E development program.

9 27. ASU granted Seattle Genetics a license on February 4, 2000 (the "License 10 Agreement"). Although the class of Auristatins that Dr. Pettit discovered includes many 11 designs, under the terms of the agreement, Seattle Genetics received a license to only four 12 specific stereoisomers of the dimethyl version of Auristatin E. Those specific 13 stereoisomers were defined in the agreement as "ASU's Patent Rights":

> Auristatin E, Compound No. 1S2R Auristatin E, Compound No. 1R2R Auristatin E, Compound No. 1S2S Auristatin E, Compound No. 1R2S Each of which falls within the general structure shown below:



21 28. The '483 patent is not limited to the four stereoisomers that were licensed to
22 Seattle Genetics under the License Agreement.

23 29. Seattle Genetics was required under the License Agreement to test and
24 develop the four licensed stereoisomers, file an investigational new drug application with
25 the FDA, and report on their development efforts.

30. Rather than use the licensed stereoisomers, however, Seattle Genetics
proceeded to develop an ADC using an unlicensed version of Auristatin E. Seattle
Genetics modified the structure of the dimethyl version of Auristatin E such that one

methyl (CH₃) group was replaced with a single hydrogen (H) atom, resulting in
 monomethyl Auristatin E ("MMAE").

3 31. Thus it appears, and ASU alleges on information and belief that Seattle
4 Genetics had no intent to actually use the licensed compounds in its research. Rather,
5 Seattle Genetics entered the agreement to obtain Dr. Pettit's confidential information
6 related to Auristatin synthesis. Indeed, Seattle Genetics used researchers who were
7 supposed to develop an ADC with Auristatin E to develop MMAE and ADCETRIS[®].

8 32. In early 2004 Seattle Genetics informed ASU that it was not going to pursue 9 an ADC using one of the four licensed stereoisomers of dimethyl Auristatin E, but instead 10 was going to use MMAE. Seattle Genetics told ASU that its development of MMAE was 11 completely independent of the compounds and information that it had received from Dr. 12 Pettit's lab at ASU and that it believed MMAE was not covered by the '483 patent. ASU 13 informed Seattle Genetics that it did not agree with Seattle Genetics' assertion that 14 MMAE was not covered by the '483 patent, but did agree that MMAE was not one of the 15 four licensed stereoisomers. In August 2004, Seattle Genetics and ASU amended the 16 License Agreement to acknowledge that MMAE was not one of the four specific 17 stereoisomers of dimethyl Auristatin E licensed under the License Agreement.

33. Seattle Genetics received FDA approval in August 2011 and began to
market an ADC using MMAE under the name ADCETRIS[®]. Seattle Genetics infringes
the '483 patent by making or having made, using, offering for sale or selling ADCETRIS[®].
Specifically, the cytotoxic drug in the ADC is MMAE, which infringes the '483 patent.
MMAE has substantially the same structure, performs the same function in substantially
the same way to achieve substantially the same results as compounds claimed in the '483
patent.

34. Seattle Genetics scientists who purported to develop MMAE have admitted
that they used Dr. Pettit's inventions in the manufacture of MMAE and reviewed the '483
patent, as well as related publications by Dr. Pettit, before designing MMAE. Indeed, in

28

-7-

1						
1	communications with Dr. Pettit, a key Seattle Genetics scientist admitted that "there is no					
2	question that the company would not be as successful if we didn't collaborate with you."					
3	35. Seattle Genetics scientists who purported to develop MMAE have admitted					
4	that Dr. Pettit's discoveries in the '483 patent were groundbreaking and novel and that Dr.					
5	Pettit's work on Auristatin E is important. Indeed, one Seattle Genetics scientist involved					
6	in the development of MMAE, who claims that he knows "more about Dolastatins than					
7	almost everyone on the planet" stated that he regarded the '483 patent as "novel" and					
8	"valid." He testified:					
9	Q: Do you consider the work that Professor Pettit did on					
10	auristatin E to be important?					
11	A: Yes.					
12						
13	C. Monomethyl Auristatin E Infringes the '483 Patent Under the Doctrine of Equivalents					
14	36. MMAE is identical to dimethyl Auristatin E except with respect to a single					
15	methyl group (CH3) which is replaced with a hydrogen atom (H). The respective					
16	chemical structures of dimethyl Auristatin E and MMAE are:					
17						
18	Auristatin E					
19						
	OH OH					
20	H,C, M, C, M, H,					
20 21	HC OH OH					
20 21 22	H,C H,C					
20 21 22 23	H_{C} H_{C					
20 21 22 23 24	H_{C} H_{C					
 20 21 22 23 24 25 	H _C H _C H _C H _C H _C H _C H _C H _C					
 20 21 22 23 24 25 26 	H _C H _C H _C H _C H _C H _C H _C H _C					
 20 21 22 23 24 25 	H ₁ C N C N C N C N C N C N C N C N C N C N					

37. The omission of a methyl group from a dimethyl Auristatin E does not alter
 the fact that the drugs perform the same function, in the same way to achieve the same
 result because of their near identity in structure except for a single methyl group, and their
 identity as to mechanism of action and function.

5 38. Seattle Genetics scientists admit that they are not aware of any differences 6 in the mechanism of action between dimethyl Auristatin E and MMAE and admit that the 7 drugs have the same function. Seattle Genetics scientist Brian Toki who developed 8 MMAE provided the following testimony under oath:

Q. Can you think of any differences, sitting here today, in its mechanism of action?

A. Between --

- Q. Between auristatin E and what you describe as monomethyl auristatin E?
- A. As in free drugs, I am not aware of any differences in mechanisms of action.

39. The omission of the methyl group from dimethyl Auristatin E is a trivial
modification that does not impact the activity or mechanism of action of the drug, as
demonstrated by Koichi Miyazaki, et al. *Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs*, Chem. Pharm. Bull., 43(10) 1706-1718 (1995).

40. As one example of the mechanism of action, when MMAE binds to tubulin,
the tubulin protein cannot polymerize. This causes microtubules to malfunction resulting
in chromosomes that are not properly separated into each daughter cell. Because each
daughter cell does not have the proper number of chromosomes each cell undergoes
apoptosis and the cells die.

25

9

10

11


12

13

14

15

- 26
- 27
- 28



ADCETRIS[®] was approved by the FDA on August 19, 2011. Since that 1 42. time ADCETRIS[®] has been successfully sold in the United States. Seattle Genetics has 2 over \$300 million in ADCETRIS[®] sales. 3

4

Claim for Infringement of U.S. Patent No. 5,635,483

5 43. ASU incorporates by reference the preceding paragraphs as though fully set 6 forth here.

7 44. On June 3, 1997, the United States Patent and Trademark Office issued 8 patent, entitled "TUMOR INHIBITING TETRAPEPTIDE BEARING the '483 MODIFIED PHENETHYL AMIDES." Seattle Genetics has infringed and is infringing, 9 10 directly or indirectly, the '483 patent by making or having made, using, offering to sell, and/or selling ADCETRIS[®] within the United States, and/or importing it into the United 11 12 States without authority. Seattle Genetics has infringed and is infringing, directly or 13 indirectly, the '483 patent by making or having made, using, offering to sell, and/or 14 selling MMAE. Seattle Genetics also infringes the '483 patent indirectly by inducing or 15 contributing to the infringement of claims for methods of inhibiting the growth of cancer cells by encouraging or directing the use of ADCETRIS[®] to inhibit the growth of cancer 16 17 cells, which Seattle Genetics knows does so by delivering and engaging such cells with 18 MMAE, which inhibits the growth of cancer cells in substantially the same way as 19 Auristatin E.

20

ADCETRIS[®] infringes at least Claims 2 and 4 of the '483 patent. 45.

21 46. ASU has been and continues to be damaged by Seattle Genetics' 22 infringement of the '483 patent, in an amount to be determined at trial.

23

47. On information and belief, Seattle Genetics' infringement has been willful 24 as Seattle Genetics knew of the '483 patent, and knew at least from its own research and 25 from Koichi Miyazaki, et al. Synthesis and Antitumor Activity of Novel Dolastatin 10 26 Analogs, Chem. Pharm. Bull., 43(10) 1706-1718 (1995) that the trivial change from the 27 dimethyl to the monomethyl version of Auristatin E did not change the effectiveness of 28 the drug or the mechanism of action.

-11-

1	48. Seattle Genetics' infringement of the '483 patent is exceptional, and thus,				
2	pursuant to 35 U.S.C. § 285, entitles ASU to its reasonable attorneys' fees and costs				
3	incurred in prosecuting this action.				
4	Prayer For Relief				
5	WHEREFORE, ASU respectfully request that this Court grant the following relief:				
6	A. That the Court enter judgment that Seattle Genetics has infringed the '483				
7	patent and that such infringement was willful;				
8	B. That ASU be awarded all damages adequate to compensate it for Seattle				
9	Genetics' infringement, such damages to be determined by a jury, and if necessary to				
10	adequately compensate ASU for the infringement, an accounting and treble damages as a				
11	result of Seattle Genetics' willful infringement;				
12	C. That ASU be awarded pre-judgment and post-judgment interest at the				
13	maximum rate allowed by law;				
14	D. That this case be declared exceptional within the meaning of 35 U.S.C. §285				
15	and that ASU be awarded its reasonable attorneys' fees, expenses, and costs incurred in				
16	connection with this action; and				
17	E. That ASU be awarded such other and further relief as this Court deems just				
18	and proper.				
19					
20	Demand For Trial by Jury				
21	ASU is entitled to and demands a trial by jury of all issues so triable.				
22					
23					
24					
25					
26					
27					
28					

	Case 2:14-cv-00653-JWS	Document	1 Filed 03/31/14	Page 13 of 13
1 2	Dated: March 31, 2014		s/ C. Mark Kittred	ge
2 3			C. Mark Kittredge K. Reed Willis	
5 4			PERKINS COIE LLI 2901 North Centra Phoenix, Arizona	1 Avenue, Suite 2000
5				
6			The Arizona Board behalf of Arizona	ttiff I of Regents for and on State University
7				
8				
9				
10	LEGAL120361166.1			
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				